Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance
-
* Corresponding author: Nicholas J White nickw@tropmedres.ac
Malaria Journal 2009, 8:253 doi:10.1186/1475-2875-8-253
Accesses
- Last 30 days: 96 accesses
- Last 365 days: 837 accesses
- All time: 3299 accesses
Cited by
BioMed Central: 4 citations
|
Research
Jessica L Cohen, Elif Yavuz, Alexandra Morris, Jean Arkedis, Oliver Sabot Malaria Journal 2012, 11:83 (23 March 2012) The paper provides useful information on a very relevant topic, i.e. the adherence to the correct treatment schedule that can be achieved in the private sector - an indication of the quality of anti-malarial treatment in that sector, a sector currently in great expansion.
|
|
Research
Poor quality vital anti-malarials in Africa - an urgent neglected public health priority Paul N Newton, Michael D Green, Dallas C Mildenhall, Aline Plançon, Henry Nettey, Leonard Nyadong, Dana M Hostetler, Isabel Swamidoss, Glenn A Harris, Kristen Powell, Ans E Timmermans, Abdinasir A Amin, Stephen K Opuni, Serge Barbereau, Claude Faurant, Ray CW Soong, Kevin Faure, Jonarthan Thevanayagam, Peter Fernandes, Harparkash Kaur, Brian Angus, Kasia Stepniewska, Philippe J Guerin, Facundo M Fernández Malaria Journal 2011, 10:352 (13 December 2011) Criminals are producing diverse harmful anti-malarial counterfeits with important public health consequences. With the threatening spread of artemisinin resistance to Africa, much greater investment is required to ensure the quality of ACT and removal of artemisinin monotherapies.
|
|
Methodology
Jennifer A Flegg, Philippe J Guerin, Nicholas J White, Kasia Stepniewska Malaria Journal 2011, 10:339 (10 November 2011) The paper presents a new tool to estimate the parasite clearance rate of Plasmodium falciparum in subjects under treatment with an artemisinin-based combination.
|
|
Methodology
Kris M Jamsen, Stephen B Duffull, Joel Tarning, Niklas Lindegardh, Nicholas J White, Julie A Simpson Malaria Journal 2011, 10:181 (1 July 2011) This article presents a novel and successful attempt to rationalize the sampling schedules for PK studies of anti-malarials given unavoidable practical constraints. It provides a practical guide to those designing population PK studies specifically of oral artesunate, and a "proof of principle" for applying optimal design methodology for anti-malarials in general.
|